Press ReleaseView printer-friendly version << Back
vTv Therapeutics to Present at 2019 Alzheimer’s Association International Conference
The presentation will highlight data from the phase 3 STEADFAST Study and preceding phase 2b study of azeliragon to further support the biological hypothesis for the potential beneficial effects of azeliragon on the ADAS-cog and CDR-sb in patients with mild Alzheimer’s disease and type 2 diabetes.
Details of the presentation are below:
Presentation Title: Linking Diabetes and Alzheimer’s Disease through RAGE.
A Retrospective Analysis of Azeliragon Phase 2 and Phase 3 Studies
Session:O4-11 Clinical: Prevention (clinical) and Human Trials - Inflammation
Date and Time:
Location: Concourse Hall 152
The presentation slides will be made available on the Publications page of the Company website.
Azeliragon, also known as TTP488, is an orally active small-molecule antagonist of the receptor for advanced glycation endproducts, RAGE.
This release contains forward-looking statements, which involve risks and uncertainties. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and, in each case, their negative or other various or comparable terminology. All statements other than statements of historical facts contained in this release, including statements regarding the timing of our clinical trials, our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause our results to vary from expectations include those described under the heading “Risk Factors” in our Annual Report on Form 10-K and our other filings with the